Sign in
NI

Natera, Inc. (NTRA)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 delivered strong top-line and margin expansion: revenue $476.1M (+53% y/y; +8% q/q) and gross margin 62.9% (+1.1pp q/q; +11.5pp y/y), with positive quarterly cash flow of ~$45.7M; net loss per share was ($0.41) versus ($0.65) a year ago .
  • 2025 guidance: revenue $1.87–$1.95B, gross margin 60–64%, SG&A $950–$975M, R&D $525–$550M, and positive net cash inflow; guidance excludes revenue “true‑ups,” with underlying Q4 gross margin ~59% ex true‑ups per management .
  • Growth drivers/catalysts: Medicare coverage expansion for Signatera in NSCLC surveillance, strengthened NCCN ctDNA guidelines, improving ASPs (Signatera clinical ASP ~$1,100 in Q4), and continued oncology test volume acceleration (Q4 oncology tests +55% y/y) .
  • Estimates context: S&P Global consensus was unavailable at time of analysis due to access limits; we cannot determine beat/miss versus the Street. Revenue modestly exceeded the company’s January pre‑announcement ($476.1M vs. ~$472M), a small positive surprise relative to internal preview .

What Went Well and What Went Wrong

What Went Well

  • Broad-based strength with mix and pricing tailwinds: revenue +53% y/y with product revenue +53.9% and gross margin up to 62.9% (from 51.4%); management highlighted realized pricing improvements and COGS reduction as key drivers .
  • Oncology momentum and reimbursement catalysts: ~150.8K oncology tests in Q4 (+54.7% y/y), Medicare coverage for Signatera surveillance in NSCLC, and NCCN upgrades (ctDNA as prognostic in CRC and positive surveillance recommendation in MCC) .
  • Cash generation and balance sheet: positive Q4 cash flow of ~$45.7M, convertible notes retired in Oct-2024, and ~$968.3M in cash/investments vs. ~$879.0M prior year-end .

Management quotes

  • “We had a strong finish to the year, with excellent performance across the board.” — CEO Steve Chapman .
  • “Signatera clinical ASPs improved to roughly $1,100 in Q4… margins [ex true-ups] ~59%.” — CEO Steve Chapman .

What Went Wrong

  • Net losses persist though narrowing: Q4 net loss ($53.8M) and ($0.41) per diluted share (vs. ($78.0M)/($0.65) y/y), with total OpEx up 49% y/y as the company invests in growth, litigation, and R&D .
  • True-ups add volatility and are excluded from 2025 guidance; management expects moderation, implying less tailwind from collections ahead .
  • Women’s health guidelines still pending on some tests (e.g., microdeletions), leaving some ASP upside contingent on future society and payer moves; management notes microdeletions improvement rests with guidelines .

Financial Results

MetricQ4 2023Q3 2024Q4 2024
Revenue ($M)$311.1 $439.8 $476.1
Gross Margin (%)51.4% 61.8% 62.9%
Net Loss per Diluted Share ($)(0.65) (0.26) (0.41)
Total Operating Expenses ($M)$244.4 $311.1 $364.4
Non-GAAP Cash Flow ($M)(60.8) 34.5 45.7

Segment/Revenue Mix

MetricQ4 2023Q3 2024Q4 2024
Product Revenues ($M)$307.3 $436.1 $472.9
Licensing & Other ($M)$3.8 $3.6 $3.2

Key KPIs

KPIQ4 2023Q3 2024Q4 2024
Tests Processed (Units)626,800 775,800 792,800
Tests Reported (Units)619,800 750,100 771,700
Oncology Tests (Units)97,500 137,100 150,800
Gross Margin ex. True-ups (Mgmt view)—>58% ~59%
Signatera Clinical ASP ($)—~1,050 ~1,100

Estimates vs. Actuals

  • S&P Global consensus estimates were unavailable due to access limits; comparisons to Street estimates are not shown. We will update when available (S&P Global data) [GetEstimates unavailable].

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Total Revenue ($B)FY 2025—1.87 – 1.95 New
Gross Margin (%)FY 2025—60 – 64 New
SG&A ($M)FY 2025—950 – 975 New
R&D ($M)FY 2025—525 – 550 New
Net Cash InflowFY 2025—Positive New
Guidance methodologyFY 2025—Excludes revenue true-ups; underlying business only Clarified

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 & Q3 2024)Current Period (Q4 2024)Trend
ASPs & True-upsSignatera ASP moving from $800s to ~$1,050; women’s health ASPs stable/improving; true-ups reflected better cash collections and expected to moderate Signatera clinical ASP ~$1,100; ~3% true-up benefit to GM in Q4; underlying GM ~59% ex true-ups; 2025 guide excludes true-ups Continued ASP gains; true-ups moderating and excluded from outlook
AI/Technology initiativesUser experience/EMR integrations; operations scaling in oncology and organ health AI tools for claims error detection, denial patterning, and custom appeal letters; >$10M data contracts signed YTD Expansion of AI across revenue cycle and data monetization
Product performance (Oncology/MRD)GALAXY OS data (Nature Medicine/ESMO) and Signatera adoption; large MRD pipeline readouts ahead NSCLC surveillance Medicare coverage; 80702 (Celecoxib) readout, early cancer detection (CRC) initial sensitivity/specificity; tissue-free MRD mid-2025 plan; genome assay traction Evidence base broadened; portfolio expanding (tumor-informed, genome, tissue-free)
Regulatory/GuidelinesAnticipated guideline evolution; organ health guideline momentum (NKF, KDIGO) NCCN strengthened ctDNA guidance in CRC (prognostic) and MCC surveillance; Medicare NSCLC surveillance coverage Positive external validation and coverage tailwinds
Reimbursement/CoverageImproving MA coverage; biomarker laws expected to help over time Formal commercial policies referencing biomarker laws; ADLT dynamics; women’s health ESC coverage expansion; first Medicaid policy for ECS in a large state Gradual, multi-year ASP uplift from policy/pricing execution
Cash Flow/Balance SheetFirst sustained cash generation; plan to reinvest while staying near breakeven ~$46M Q4 cash inflow; convert retired; ~$968M cash/investments; target positive cash 2025 Strengthening liquidity and operating leverage
Seasonality/CadenceExpect modest sequential growth; Q2 women’s health seasonality 2025 cadence: strong Q1 in women’s health; Q2 seasonal softness; Signatera less seasonal; receiving days matter Normal seasonality returning; oncology steady

Management Commentary

  • Strategic focus on pricing and COGS: “Gross margins in the quarter were 63%... highlights the progress we made on both COGS and realized pricing in 2024.” — CEO Steve Chapman .
  • Durable ASP runway: “We think we could see the revenue per test effectively double as we start to get paid for some of the tests that we run today…” — CEO Steve Chapman .
  • Capital allocation: “On our current trajectory, we could begin to generate meaningful cash flows in 2025… take the cash flows we are generating and reinvest them in the business in 2025.” — CEO Steve Chapman .
  • Coverage/guidelines: “We were pleased by the recent [NCCN] guideline updates… and [NSCLC] surveillance coverage… a big step forward” — Executives .

Q&A Highlights

  • ASP pathway and doubling potential: Management noted revenue per test could “effectively double” over time as coverage/payer compliance expands; near-term Signatera ASP improvement driven by Medicare Advantage coverage progress (now “high 60s%” allowed rates) .
  • True-ups path: True-ups expected to moderate on a “glide slope” as accruals catch up to better cash collections; excluded from 2025 guide due to lumpiness .
  • Signatera volumes: Guide assumes >8–10K sequential quarterly unit growth; Q1 tracking among best quarters historically .
  • NSCLC coverage impact: New surveillance coverage broadens addressable opportunity; payer mix broadly similar to average, bundle pricing framework expected .
  • Product roadmap: Genome-based MRD tracks 64 variants; tissue-free CRC MRD planned mid-2025; early cancer detection (CRC) initial readouts (CRC sensitivity up to 95% in combined datasets; advanced adenoma 18% sensitivity at 91% specificity) .

Estimates Context

  • S&P Global consensus for Q4 2024 and FY 2025 was unavailable due to access limits at the time of analysis; we cannot assess beat/miss versus the Street now (S&P Global data pending).
  • Relative to internal preview, revenue slightly exceeded January pre-announcement ($476.1M actual vs. ~$472M pre-announced) and management emphasized Q4 gross margin outperformance including true-ups .

Key Takeaways for Investors

  • NTRA exited 2024 with accelerating revenue and structural margin expansion, supported by mix shift to Signatera, realized pricing, and COGS progress; positive cash generation adds flexibility .
  • 2025 guide appears conservative (excludes true-ups), with multiple upside levers: biomarker-law adoption, NCCN tailwinds, Medicare NSCLC surveillance, and ongoing ASP gains—especially in Signatera .
  • Oncology franchise durability: expanding indications, strong clinical/economic evidence, and new modalities (genome, tissue-free) position Natera well against competition .
  • Watch for data catalysts: further publications (e.g., 80702 full publication, IMvigor011 in 2025), tissue-free launch (mid-2025), and ECD trial updates; positive reads could shift guideline and payer behavior .
  • Risk checks: true-ups moderation reduces ancillary tailwinds; OpEx is rising (R&D/SG&A) to support growth; continued execution on reimbursement (commercial & Medicaid) remains critical .
  • Trading lens: catalysts include additional coverage decisions, NCCN evolution, sequential Signatera growth above the 8–10K baseline, and sustained gross margin progression; setbacks in key clinical readouts or slower biomarker-law adoption are the main downside risks near term .

Appendix: Additional KPIs and Footnotes

  • Balance sheet: Cash, cash equivalents, short-term investments, and restricted cash at 12/31/24: ~$968.3M; debt: ~$80.4M UBS LOC; convert redeemed/converted 10/11/24 .
  • Test mix summary (company table): see PR and 8‑K exhibits for quarterly and annual processed, accessioned, and reported tests .
  • Conference logistics and investor presentation were furnished in 8‑K exhibits .